All Eyes On Pricing Model As EU Crunch Time Nears For First Ophthalmic Bevacizumab

 
• By Neena Brizmohun

If Outlook Therapeutics’ Lytenava secures EU approval for wet AMD, the company says it expects to price the drug as a lower cost alternative to biosimilars and premium branded products for the condition, and higher than off-label compounds.

EU flag reflected in eye
EMA to decide on EU marketing application for wet AMD drug Lytenava • Source: Shutterstock

More from Europe

More from Geography